Source:http://linkedlifedata.com/resource/pubmed/id/15914370
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2005-5-25
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0925-5710
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
81
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
356-7
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15914370-Antibodies, Monoclonal,
pubmed-meshheading:15914370-Antirheumatic Agents,
pubmed-meshheading:15914370-Arthritis, Rheumatoid,
pubmed-meshheading:15914370-Female,
pubmed-meshheading:15914370-Humans,
pubmed-meshheading:15914370-Lymphoproliferative Disorders,
pubmed-meshheading:15914370-Middle Aged,
pubmed-meshheading:15914370-Risk Factors
|
pubmed:year |
2005
|
pubmed:articleTitle |
Infliximab-associated lymphoproliferative disorders.
|
pubmed:publicationType |
Letter,
Case Reports,
Research Support, Non-U.S. Gov't
|